NSE: GLAND | BSE: 543245

Mid-range Performer

Download real time

1728.50 12.10 (0.70%)

28.80% Gain from 52W Low

42,311 NSE+BSE Volume

NSE 08 Apr, 2026 3:31 PM (IST)

28,478.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

29 Jan 2026

1728.50

0.70%

Result Update:Gland Pharma

Buy: Gland Pharma Ltd.

Recommendation

Axis Direct

We maintain our BUY rating on the stock.

Number of FII/FPI investors decreased from 260 to 236 in Dec 2025 qtr

Gland Pharma Ltd.

29 Jan 2026

1728.50

0.70%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in...

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.

Gland Pharma Ltd.

28 Jan 2026

1728.50

0.70%

Cenexi break-even/US uptrend drives earnings beat

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered better-than-expected 3QFY26 financial performance with a 6%/14%/19% beat on revenue/EBITDA/PAT.

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.

Gland Pharma Ltd.

04 Nov 2025

1728.50

0.70%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We revise our rating from HOLD to BUY

Gland Pharma Ltd. is trading below its 50 day SMA of 1754.4

Gland Pharma Ltd.

04 Nov 2025

1728.50

0.70%

Gland Pharma

Buy: Gland Pharma Ltd.

ICICI Direct

Number of FII/FPI investors decreased from 260 to 236 in Dec 2025 qtr

Gland Pharma Ltd.

04 Nov 2025

1728.50

0.70%

In-line revenue; margin miss transient

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lowerthan-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance.

Number of FII/FPI investors decreased from 260 to 236 in Dec 2025 qtr

Gland Pharma Ltd.

06 Aug 2025

1728.50

0.70%

Strong margin gain boosts PAT by 50% YoY

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat).

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.

Gland Pharma Ltd.

06 Aug 2025

1728.50

0.70%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating on the stock with a target price of Rs 1,950/share.

Number of FII/FPI investors decreased from 260 to 236 in Dec 2025 qtr

Gland Pharma Ltd.

04 Feb 2025

1728.50

0.70%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating with a target price of Rs 1,580, implying an upside potential of 4%, valuing the company at a PE of 20x for FY27.

Gland Pharma Ltd. is trading below its 50 day SMA of 1754.4

Gland Pharma Ltd.

03 Feb 2025

1728.50

0.70%

New launches and higher milestone income drive margins

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (Gland) delivered a better-than-expected operating performance for the quarter. While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business.

Number of FII/FPI investors decreased from 260 to 236 in Dec 2025 qtr

VOTE: Is Gland Pharma Ltd. worth buying?

215 Votes:

Buy 80.93%

Sell 9.3%

Hold 9.77%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf